ORLANDO — In this video from the American Academy of Ophthalmology meeting, David A. Eichenbaum, MD, FASRS, discusses phase 2b ASPIRE study results comparing UBX1325 vs. aflibercept in patients with diabetic macular edema.
In the phase 2b study, researchers randomly assigned patients with DME to receive intravitreal UBX1325 10 µg (foselutoclax, Unity Biotechnology) or Eylea (aflibercept 2 mg, Regeneron).
At 36 weeks, UBX1325 was noninferior to aflibercept when compared head-to-head to aflibercept every 8 weeks following loading, but the primary endpoint was not met.
“At the mean